Gujarat Themis Biosyn Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GUJTHEM, BSE:506879 Gujarat Themis Biosyn Ltd.

Search Inside the pdf :

Gujarat Themis Biosyn Ltd.

25 Jan 2026

335.75

2.60%

Gujarat Themis Biosyn Limited Tgt 367

Buy: Gujarat Themis Biosyn Ltd.

BP Wealth

Gujarat Themis Biosyn Limited (GTBL), incorporated in 1981, is an Indian pharmaceutical company specialising in the manufacturing of fermentation-based pharmaceutical intermediates and APIs. The company focuses on niche and critical intermediates, primarily Rifamycin S and Rifamycin O, which are key inputs for Rifampicin and Rifaximin antibiotics widely used in the treatment of tuberculosis and bacterial infections. GTBL operates state-of-the-art fermentation facilities at Vapi with an expanded installed capacity of ~990 KL, enabling scalable production with high cost efficiency, consistent quality, and operational flexibility across multiple fermentation products. The niche nature of Rifamycin intermediates used in critical therapies such as tuberculosis ensures stable demand and strategic importance. Additionally, the company's ongoing investments in R&D, new molecule development, and forward integration into APIs further reinforce its positioning by deepening technical complexity and customer stickiness. The company previously considered a merger with Themis...

Gujarat Themis has gained 35.08% in the last 1 Year

Is Gujarat Themis Biosyn Ltd. worth buying?

171 Votes:

Buy 78.36%

Sell 12.28%

Hold 9.36%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf